Tocilizumab (TCZ) for Giant Cell Arteritis: Clinical Outcomes Following Relapses and TCZ Discontinuation Due to Adverse Events
Although GCA relapses can occur after initiating TCZ therapy, most relapses can be safely managed by adjusting TCZ, GC, and/or MTX doses. Adding IST or biologic treatments may potentially be related to preventing relapses when patients discontinue TCZ because of AEs.
Authors
- Naoho Takizawa (ORCID: https://orcid.org/0000-0003-3744-3537)
- Ryo Rokutanda (ORCID: https://orcid.org/0000-0001-5966-6403)
- Masahiro Minoda
- Nobuhiro Oda (ORCID: https://orcid.org/0000-0003-3967-6414)
- Mitsuru Watanabe (ORCID: https://orcid.org/0000-0003-0831-623X)
- Yoichiro Haji (ORCID: https://orcid.org/0000-0001-5594-9123)
- Masei Suda (ORCID: https://orcid.org/0000-0002-2036-6216)
- Fumika N. Nagase (ORCID: https://orcid.org/0000-0003-0737-282X)
- Sho Fukui (ORCID: https://orcid.org/0000-0002-3082-1374)
- Toshihiro Yamaguchi
- Yasuhiro Suyama (ORCID: https://orcid.org/0000-0002-9298-9121)
- Hiromichi Tamaki (ORCID: https://orcid.org/0009-0009-9620-9995)
- Eishi Uechi
- Atsushi Nomura (ORCID: https://orcid.org/0000-0002-8194-6273)
- Hajime Inokuchi
- Takanori Ito (ORCID: https://orcid.org/0000-0002-1879-3550)
Institutions
- NTT Medical Center (JP)
- St. Luke's International Hospital (JP)
- Chubu Rosai Hospital (JP)
- Kameda Medical Center (JP)
- Kawamura Hospital (JP)
- Tomishiro Central Hospital (JP)
- Sakurabashi Watanabe Hospital (JP)
- Suwa Red Cross Hospital (JP)
- Daido University (JP)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.3899/jrheum.2024-0612
- Citations
- 3
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.26